Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase – Still a Buy?

Genmab A/S (NASDAQ:GMAB) shares saw unusually-high trading volume on Wednesday . Approximately 1,146,722 shares were traded during mid-day trading, an increase of 99% from the previous session’s volume of 577,457 shares.The stock last traded at $23.57 and had previously closed at $23.59.

Wall Street Analyst Weigh In

GMAB has been the subject of several recent research reports. BTIG Research boosted their price target on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Friday, September 20th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $31.00 target price on shares of Genmab A/S in a research report on Wednesday, September 11th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Genmab A/S currently has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Trading Up 0.3 %

The company has a market capitalization of $15.64 billion, a P/E ratio of 19.71, a PEG ratio of 0.73 and a beta of 0.98. The stock has a 50 day moving average price of $26.36 and a 200 day moving average price of $27.44.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.07). The firm had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. On average, research analysts predict that Genmab A/S will post 1.27 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. grew its stake in shares of Genmab A/S by 137.7% in the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after purchasing an additional 544 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock valued at $34,000 after buying an additional 749 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Genmab A/S during the first quarter worth about $43,000. Barometer Capital Management Inc. acquired a new stake in Genmab A/S during the 4th quarter valued at approximately $121,000. Finally, Headlands Technologies LLC lifted its position in shares of Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after purchasing an additional 4,853 shares during the period. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.